Skip to Main Content

Advertisement

Skip Nav Destination

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

December 30, 2021
On location

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement